The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

For the past year, Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the newer, high-demand drugs now known as "weight-loss" shots: Mounjaro, ...

Meanwhile, Lilly also confirmed that it will start running a head-to-head cardiovascular outcomes trial for Trulicity and one of its pipeline diabetes candidates – dual GIP/GLP1 agonist ...

Eli Lilly and Company discovers ... and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including ...

Those at risk include people living with type 2 diabetes or high blood pr Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing ...

but taking into account the huge need there would probably continue to be supply constraints until we had an oral medicine with an injectable-like efficacy,” President of Lilly Diabetes and ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies – but still said sales rose around a third over the prior year.

Shares of Eli Lilly & Co. were headed for their worst ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...

2024 revenue forecast: $45.0 billion (+32% YoY), below the $45.50 billion consensus. 2025 revenue guidance: $58.0 billion to $61.0 billion, driven by new medicines and global expansions.

Beyond revenue growth in diabetes and obesity, Lilly’s strategy includes expanding use of tirzepatide to other indications. In late December, the FDA approved Zepbound as a treatment for ...

I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly ... year growing share in diabetes. We're now the NBRx ...